Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment

Bone marrow transplantation is regarded as the most effective immunotherapy for hematologic cancer, but it generally faces difficulties in matching. Aberrant expression of histone deacetylases (HDACs) is closely related to the occurrence and development of hematological cancer. Recent studies suggested that HDACs might play a critical role in initiating anti-cancer immune response or enhancing anti-cancer immunotherapy. Besides, combining HDAC inhibition and immunotherapy could prevent immunotherapy resistance in some degree and reach an extended treatment window. This review summarized the relationship between HDACs and immune and described the current understanding of HDACs in immunotherapy for hematologic cancer.

Automated summary

Bone marrow transplantation is an effective immunotherapy for hematologic cancer, but matching is often challenging. Aberrant expression of histone deacetylases (HDACs) is closely associated with the occurrence and development of hematologic cancer. Recent studies have shown that HDACs may play a critical role in initiating anti-cancer immune response or enhancing immunotherapy.